Cancer 'Vaccine' Wiped Out Tumors In Mice, Scientists Say

Stanford researchers develop cancer ‘vaccine’ that wipes out tumors in mice

Researchers at the Stanford University School of Medicine injected a cancer vaccine in 90 mice, and majority were cured.

The boosters reinvigorated the T-cells, allowing the cells to destroy the tumors and related cancer that had metastasized throughout the mice.

Unlike other cancer treatments already in the market and that involves a lengthy treatment process and comes with rough side effects besides being expensive, the new method is simpler. Researchers say they've "developed a practical strategy for immunotherapy of cancer" In 90 mice, the technique eliminated cancer in 87. immunoenhancing agents were injected directly into the rodents' tumors, triggering a local T-cell immune response and going on to attack cancer throughout the entire body.

"This approach bypasses the need to identify tumour-specific targets and doesn't require wholesale activation of the immune system or customisation of a patient's immune cells". The other has been tested for human use in several unrelated clinical trials, according to the report. The other is being tested for possible use on human patients.

Eventually, Levy said he envisions a future in which clinicians inject the two agents into solid tumors in humans prior to surgical removal of the cancer, which, Levy hopes, would prevent any recurrence of any cancerous tumor in the body. Once these cells are created, they are "prescreened" to only recognize cancer-specific proteins.

"I don't think there's a limit to the type of tumor we could potentially treat, as long as it has been infiltrated by the immune system", said Dr. Ronald Levy, professor of oncology.

Treating the first tumour that arose often prevented the occurrence of future tumours and significantly increased the animals' lifespan. Researchers say it is also a rapid and relatively low-cost cancer therapy. Researchers also saw similar results in mice bearing breast, colon and melanoma tumors.

One of the two immune-stimulating agents in the "vaccine" has already been approved for use in humans.

For the trial, Levy plans to recruit 15 patients with low-grade cancers. Although the injection was successful in eliminating the targeted tumors present in the mouse, the T cells did not move on to a colon cancer tumor also found in the animal.



Other news